Showing 2640 results
- Media Release /Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
- Media Release /Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
- Media Release /Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
- Media Release /Shareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well…
- Media Release /Les actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur…
- Media Release /Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des…
- Media Release /If approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the…
- Media Release /Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
- Media Release /Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
- Media Release /US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
Pagination
- ‹ Previous page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- …
- 264
- › Next page